Pharmacological Strategies for Stroke Intervention: Assessment of Pathophysiological Relevance and Clinical Trials.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2023-01-01 DOI:10.1097/WNF.0000000000000534

Geetesh Verma, Deepaneeta Sarmah, Aishika Datta, Avirag Goswami, Nikita Rana, Harpreet Kaur, Anupom Borah, Sudhir Shah, Pallab Bhattacharya

{"title":"Pharmacological Strategies for Stroke Intervention: Assessment of Pathophysiological Relevance and Clinical Trials.","authors":"Geetesh Verma, Deepaneeta Sarmah, Aishika Datta, Avirag Goswami, Nikita Rana, Harpreet Kaur, Anupom Borah, Sudhir Shah, Pallab Bhattacharya","doi":"10.1097/WNF.0000000000000534","DOIUrl":null,"url":null,"abstract":"Objectives: The present review describes stroke pathophysiology in brief and discusses the spectrum of available treatments with different promising interventions that are in clinical settings or are in clinical trials.Methods: Relevant articles were searched using Google Scholar, Cochrane Library, and PubMed. Keywords for the search included ischemic stroke, mechanisms, stroke interventions, clinical trials, and stem cell therapy.Results and conclusion: Stroke accounts to a high burden of mortality and morbidity around the globe. Time is an important factor in treating stroke. Treatment options are limited; however, agents with considerable efficacy and tolerability are being continuously explored. With the advances in stroke interventions, new therapies are being formulated with a hope that these may aid the ongoing protective and reparative processes. Such therapies may have an extended therapeutic time window in hours, days, weeks, or longer and may have the advantage to be accessible by a majority of the patients.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 1","pages":"17-30"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The present review describes stroke pathophysiology in brief and discusses the spectrum of available treatments with different promising interventions that are in clinical settings or are in clinical trials.

Methods: Relevant articles were searched using Google Scholar, Cochrane Library, and PubMed. Keywords for the search included ischemic stroke, mechanisms, stroke interventions, clinical trials, and stem cell therapy.

Results and conclusion: Stroke accounts to a high burden of mortality and morbidity around the globe. Time is an important factor in treating stroke. Treatment options are limited; however, agents with considerable efficacy and tolerability are being continuously explored. With the advances in stroke interventions, new therapies are being formulated with a hope that these may aid the ongoing protective and reparative processes. Such therapies may have an extended therapeutic time window in hours, days, weeks, or longer and may have the advantage to be accessible by a majority of the patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

卒中干预的药理学策略:病理生理学相关性评估和临床试验。

目的:本综述简要描述了脑卒中的病理生理学，并讨论了在临床环境或临床试验中不同有希望的干预措施的可用治疗范围。方法:通过Google Scholar、Cochrane Library和PubMed检索相关文献。搜索的关键词包括缺血性卒中，机制，卒中干预，临床试验和干细胞治疗。结果和结论:中风是全球范围内死亡率和发病率的高负担。时间是治疗中风的一个重要因素。治疗选择有限;然而，具有相当疗效和耐受性的药物仍在不断探索中。随着中风干预的进展，新的治疗方法正在制定，希望这些可能有助于正在进行的保护和修复过程。这种疗法可能具有延长的治疗时间窗口，如数小时、数天、数周或更长时间，并且可能具有大多数患者可获得的优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.